Cell Apps Flyer Human iPSC
Instructions 017DK i-HCm Differentiation Medium Kit
Integration-free HiPSC. Our HiPSC are generated with the RNA-based Sendai virus to deliver reprogramming factors to donor skin fibroblasts. Since the virus does not go through a DNA phase, its genetic material and transgenes do not integrate into the host cell genome. HiPSC are validated for viability, karyotype, pluripotency, plating efficiency, morphology, passage number and lack of contamination.
HiPSC-derived Neural Stem Cells (L) and Neurons (R). i-HNSC stained w/ Nestin (neural stem cell marker, green), SOX 2 (stem cell marker, red) & DAPI (nuclear stain, blue). SOX2 & DAPI nuclear co-localization yields purple (Left). Video: Human iPSC-Derived Neurons establish mature, synchronized neuronal network. In real time, Multi-electrode array (MEA) shows optimal electrophysiological activity, which can be modulated by neurotransmitters or small compounds (Right).
HiPSC-derived Cardiomyocytes (i-HCM) plated onto a flat culture surface pulsate in vitro (L), while iHCM printed into 3D heart tissue using a Cyfuse Regenova also beat (R)
Reprogramming triggers a cascade of evident changes in the host cells that are recognizable morphologically and through a combination of markers and pluripotency assays. Our HiPSCs display classic pluripotent stem cell morphology, with a high nucleus to cytoplasm size ratio, as well as they are amenable to be cultivated in serum-free media, independent of feeder cells and of feeder-conditioned media as colonies or high density monolayers. hiPSCs are also evaluated for the presence of karyotypic abnormalities. Confirmation of pluripotency is performed through the analysis of expression of several established independent pluripotency markers. Unguided differentiation confirms HiPSC ability to generate cell derivatives of tissues arising from the three embryonic layers.
Cell Characterization. Post-thawing viability of HiPSCs is typically higher than 70%, and HiPSC have demonstrated coherent pluripotent behavior over more than 60 passages. Although it is in theory possible to propagate HiPSCs indefinitely, HiPSC subculturing over passages higher than is usually not recommended, as the chances of karyotypic abnormalities increase. HiPSCs are also tested to ensure absence of microorganism contaminants.
For Research Use Only - Not for Human or Clinical Applications
|Source||Neonatal Male (iPS11-10) or Adult Female (iPS12-10) human dermal fibroblasts (single donor), reprogrammed w/ replication-deficient Sendai virus|
|QC||No bacteria, yeast, fungi, mycoplasma, virus (Trace Sendai virus possible)|
|CofA||Donor, gender, tissue source, disease status, cell viability (post-thaw), plating efficiency, passage #, karyotype, pluripotency|
|Cryovial||1,000,000 HiPSC (low passage) frozen in serum-free HiPSC Freezing Medium|
|Medium||Cells manufactured, maintained in serum-free, feeder-free culture conditions|
|Doublings||At least 60 w/out lost morphology, phenotype|
|Bioassay||PSC morphology, growth behavior when grown in pluripotency conditions|
|Applications||Non-commercial research use only (RUO), not for human or clinical use|
HiPSC Total Kits
(See HiPSC Medium for details)
|1ml||iPS11-10 or iPS12-10||LN2|
Basal Med (014-500)
Gr Supp (015XF-GS)
|Coating Solution, Xeno-Free||25ml||126XF-25||-20C|
Dissoc Soln (076-25)
|Cryopreserved Human Induced Pluripotent Stem Cell Total Kit, neonatal, male: 1x10^6 Cells, Medium, Coating Solution & Dissociation Soln (See Details tab for gender & specifics)||Size: 1 Kit||CAT.#: iPS11K-10||Price: $1,052.00|
|Cryopreserved HiPSC, from neonatal Male Dermal Fibroblasts: Frozen Human Induced Pluripotent Stem Cells derived from HDF (1x10^6) (Donor age, gender in details)||Size: 1 Cryovial||CAT.#: iPS11-10||Price: $692.00|
|Cryopreserved Human Induced Pluripotent Stem Cell Total Kit, adult, female: 1x10^6 Cells, Coating Solution, Medium & Dissociation Soln (See Details tab for gender & specifics)||Size: 1 Kit||CAT.#: iPS12K-10||Price: $1,052.00|
|Cryopreserved HiPSC, from adult Female Dermal Fibroblasts: Frozen Human Induced Pluripotent Stem Cells derived from HDF (1x10^6) (Donor age, gender in Details Tab)||Size: 1 Cryovial||CAT.#: iPS12-10||Price: $692.00|
|HiPSC Growth Medium: All-in-one ready-to-use, growth supplements pre-added, no mixing necessary. Recommend use within 2 weeks (Or use Kit for longer storage).||Size: 500 ml||CAT.#: 015XF-500||Price: $227.00|
|HiPSC Growth Medium Kit: Basal medium and growth supplement packaged separately||Size: Yields 500 ml||CAT.#: 015XFK-500||Price: $233.00|
|HiPSC Coating Solution: EHS Matrix Extract, pre-diluted and ready-to-use for coating tissue culture ware||Size: 100 ml||CAT.#: 126-100||Price: $50.00|
|HiPSC Coating Solution, Xeno-Free: Truncated Vitronectin, no animal components, pre-diluted and ready-to-use for coating tissue culture ware||Size: 100 ml||CAT.#: 126XF-100||Price: $175.00|
|HiPSC Dissociation Kit: 50 ml Dissociation Solution and 100 ml PBS, for subculture (passaging) of Human Induced Pluripotent Stem Cells||Size: 1 Kit||CAT.#: 091K||Price: $58.00|
|HiPSC Freezing Medium: Serum-free freezing medium optimized for HiPSC||Size: 50 ml||CAT.#: 045-50||Price: $198.00|
|Human Cardiomyocyte Differentiation Medium Kit: Differentiation, Selection & Maintenance Media sold together, packaged separately. See Details Tab.||Size: 1 Kit||CAT.#: 017DK||Price: $288.00|
Extended Family Products
|Mouse ACTA2 Antibody: Mouse ACTA2 Antibody||Size: 100 ul||CAT.#: CP10399||Price: $302.00|
|Mouse Beta-Actin Antibody: Mouse beta-Actin Antibody||Size: 100 ul||CAT.#: CP10003||Price: $302.00|
|Mouse Beta-Actin Antibody: Beta-Actin Mouse Monoclonal Antibody||Size: 100 ul||CAT.#: CC10028||Price: $302.00|
|Mouse Lin28 Antibody: Mouse Lin28 Antibody||Size: 100 ul||CAT.#: CP10153||Price: $333.00|
|Mouse Nanog Antibody: Mouse Nanog Antibody||Size: 100 ul||CAT.#: CP10180||Price: $333.00|
|Rabbit Oct4 Antibody: Rabbit Oct4 Antibody||Size: 100 ul||CAT.#: CG1367||Price: $384.00|
|Mouse Oct4 Antibody: Mouse Oct4 Antibody||Size: 100 ul||CAT.#: CP10290||Price: $333.00|
|Mouse Tcf3 Antibody: Mouse Tcf3 Antibody||Size: 100 ul||CAT.#: CP10234||Price: $302.00|
|Cyto-X Cell Counting Reagent: 500 tests||Size: 1 Bottle||CAT.#: 028-01||Price: $160.00|
|Cyto-X Cell Counting Reagent Sample: 100 tests||Size: Sample||CAT.#: 028-S||Price: $41.00|
|Cytofect Cell Line Transfection Kit (250 x 24-Wells): 250 x 24-Well Rxns||Size: 1 Kit||CAT.#: TF104K||Price: $291.00|
|Cytofect Cell Line Transfection Sample Kit (25 x 24-Wells): 25 x 24-Well Rxns||Size: 1 Sample Kit||CAT.#: TF104KS||Price: $62.00|
Cell Apps Flyer Human iPSC
Format: PDFDownoad Now
Ma, X., X. Qu, W. Zhu, Y. Li, S. Yuan, H. Zhang, J. Liu, P. Wang, C. Lai, F. Zanella, G. Feng, F. Sheikh, S. Chien and S. Chen. 2016. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting. Proc Natl Acad Sci, 113:2206-2211.
Hribar, K., D. Finlay, X. Ma, X. Qu, M. Ondeck, P. Chung, F. Zanella, A. Engler, F. Sheikh, K Vuori and S. Chen. 2015. Nonlinear 3D projection printing of concave hydrogel microstructures for long-term multicellular spheroid and embryoid body culture. Lab on a Chip, 7:2412-2418.
Zanella F., R. Contu, R. Lyon, V. Mezzano, A. Castaneda, S. Perez, J. Wojciak, J. Roberts, C. Carromeu, G. Keller, A. Muotri, M. Scheinman and F. Sheikh. 2015. Arrhythmogenic Right Ventricular Cardiomyopathy hiPSC-derived cardiomyocytes show disease phenotypes correlating with clinical data from donor patients. ASCB, B1678/P2419 (118).
Zanella F., R. Contu, R. Lyon, V. Mezzano, A. Castaneda, S. Perez, J. Wojciak, J. Roberts, C. Carromeu, G. Keller, A. Muotri, M. Scheinman and F. Sheikh. 2014. Human Induced Pluripotent Stem Cells Recapitulate Disease Manifestations and Severities of Patients with Arrhythmogenic Cardiomyopathy. Stem Cell Meeting on the Mesa.
Zanella F, V. Mezzano, R. Lyon, C. Carromeu, G. Keller, A. Muotri, M. Scheinman and F. Sheikh. 2013. Human induced pluripotent stem cell models to uncover mechanisms underlying varying clinical symptoms associated with Arrhythmogenic Cardiomyopathy. Cell Symposia: Using Stem Cells To Model and Treat Human Disease, Session I: Modeling Disease Using Stem Cells.